![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
INFLAMMATION AND IMMUNOPHARMACOLOGY
-Melanocyte-Stimulating Hormone Peptides
The William Harvey Research Institute, London, UK (S.J.G., M.P.); and Department of Neuroscience, Uppsala University, Uppsala, Sweden (H.S.)
In this study, we analyzed the anti-inflammatory effects of 
-melanocyte stimulating hormone (MSH)11–13 (KPV) in comparison with other MSH peptides in a model of crystal-induced peritonitis. Systemic treatment of mice with KPV, -MSH, the core melanocortin peptide His-Phe-Arg-Trp, and the melanocontin receptor 3/4 agonist Ac-Nle4-c[Asp5,D-Phe7,Lys10]NH2 ACTH4-10 (MTII) but not the selective MC1-R agonist H-Ser-Ser-Ile-Ile-Ser-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 (MS05) resulted in a significant reduction in accumulation of polymorphonuclear leukocyte in the peritoneal cavity. The antimigratory effect of KPV was not blocked by the MC3/4-R antagonist Ac-Nle4-c[Asp5,D-2Nal7,Lys10]NH2 ACTH4-10 (SHU9119). In vitro, macrophage activation, determined as release of KC and interleukin (IL)-1
was inhibited by -MSH and MTII but not by KPV. Furthermore, macrophage activation by MTII led to an increase in cAMP accumulation, which was attenuated by SHU9119, whereas KPV failed to increase cAMP. The anti-inflammatory properties of KPV were also evident in IL-1-induced peritonitis inflammation and in mice with a nonfunctional MC1-R (recessive yellow e/e mice). In conclusion, these data highlight that the C-terminal MSH peptide KPV exhibits an anti-inflammatory effect that is clearly different from that of the core MSH peptides. KPV is unlikely to mediate its effects through melanocortin receptors but is more likely to act through inhibition of IL-1 functions.
Address correspondence to: Dr. Stephen J. Getting, Department of Biochemical Pharmacology, The William Harvey Research Institute, Charterhouse Square, London EC1M 6BQ, UK. E-mail: s.j.getting{at}qmul.ac.uk
This article has been cited by other articles:
|
|
 |
|
  T. Brzoska, T. A. Luger, C. Maaser, C. Abels, and M. Bohm {alpha}-Melanocyte-Stimulating Hormone and Related Tripeptides: Biochemistry, Antiinflammatory and Protective Effects in Vitro and in Vivo, and Future Perspectives for the Treatment of Immune-Mediated Inflammatory Diseases Endocr. Rev., August 1, 2008; 29(5): 581 - 602. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A Luger and T. Brzoska {alpha}-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs Ann Rheum Dis, November 1, 2007; 66(suppl_3): iii52 - iii55. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Catania The melanocortin system in leukocyte biology J. Leukoc. Biol., February 1, 2007; 81(2): 383 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Kang, K. W. McIntyre, K. M. Gillooly, Y. Yang, J. Haycock, S. Roberts, A. Khanna, T. F. Herpin, G. Yu, X. Wu, et al. A selective small molecule agonist of the melanocortin-1 receptor inhibits lipopolysaccharide-induced cytokine accumulation and leukocyte infiltration in mice J. Leukoc. Biol., October 1, 2006; 80(4): 897 - 904. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Maaser, K Kannengiesser, C Specht, A Lugering, T Brzoska, T A Luger, W Domschke, and T Kucharzik Crucial role of the melanocortin receptor MC1R in experimental colitis Gut, October 1, 2006; 55(10): 1415 - 1422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. W. Lam, S. J. Getting, and M. Perretti In Vitro and In Vivo Induction of Heme Oxygenase 1 in Mouse Macrophages following Melanocortin Receptor Activation J. Immunol., February 15, 2005; 174(4): 2297 - 2304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Catania, S. Gatti, G. Colombo, and J. M. Lipton Targeting Melanocortin Receptors as a Novel Strategy to Control Inflammation Pharmacol. Rev., March 1, 2004; 56(1): 1 - 29. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
